KYNB
KYNTRA BIO, INC.
-0.06 (-0.79%)7.55USD6.2K成交股數30.6M市值0.2本益比(近四季)6.6股價營收比-209.3%營收年增(近四季)2026-11-09下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | −1.5M-209% | 3.7M+36% | 1.3M+938% | 1.1M+8% | 1.3M-95% | 2.7M-104% | 123K-100% | 998K-98% | 25.4M | −73.8M | 40.1M | 44.3M |
| 營業成本 | 2K | 4.1M | 277K | −58K | 85K | 252K | −75K | 140K | 21.3M | −9.5M | 4.2M | 5.7M |
| 毛利 | −1.5M-217% | −368K-115% | 1.0M+405% | 1.1M+32% | 1.3M-69% | 2.5M-104% | 198K-99% | 858K-98% | 4.0M | −64.3M | 35.9M | 38.6M |
| 毛利率 | 100.1% | -9.8% | 78.3% | 105.4% | 93.7% | 90.8% | 161.0% | 86.0% | 15.9% | 87.2% | 89.4% | 87.1% |
| 研發費用 | 6.8M | 7.6M | 7.3M | 1.2M | 5.9M | 9.2M | 20.0M | 32.4M | 36.5M | 35.3M | 61.2M | 95.5M |
| 銷售管理費用 | 9.3M | 5.9M | 7.3M | 5.3M | 7.1M | 8.1M | 9.4M | 14.9M | 16.7M | −4.5M | 25.6M | 31.2M |
| 營業利益 | −17.6M+46% | −13.8M-7% | −13.5M-72% | −5.4M-88% | −12.1M-75% | −14.9M-84% | −47.7M-25% | −46.4M-47% | −49.2M | −95.1M | −63.5M | −88.0M |
| 營業利益率 | 1,192.3% | -369.7% | -1,058.1% | -502.9% | -894.1% | -544.7% | -38,774.0% | -4,650.1% | -193.9% | 128.8% | -158.2% | -198.7% |
| 稅後淨利 | 12.0M-257% | −15.2M-428% | −14.2M-17% | 201M-1391% | −7.6M-77% | 4.6M-108% | −17.1M-73% | −15.5M-82% | −32.9M | −56.2M | −63.6M | −87.7M |
| 淨利率 | -812.3% | -406.6% | -1,113.5% | 18,646.5% | -564.0% | 169.4% | -13,889.4% | -1,557.5% | -129.8% | 76.2% | -158.5% | -197.8% |
| 稀釋 EPS | 2.96-257% | -3.76-427% | -3.51-17% | 49.61-1375% | -1.88+470% | 1.15-305% | -4.25+554% | -3.89+332% | -0.33 | -0.56 | -0.65 | -0.90 |
| 稀釋股數 | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 99.0M | 97.3M | 98.2M | 97.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 50.6M | 37.0M | 47.9M | 118M | 23.4M | 33.6M | 131M | 141M | 106M | 81.6M | 121M | 153M |
| 應收帳款 | 347K | 5.0M | 216K | 121K | 136K | 147K | 29.0M | 6.4M | 37.1M | 5.1M | 31.7M | 25.6M |
| 存貨 | 3.4M | 3.4M | 3.7M | 3.9M | 3.9M | 3.2M | 23.9M | 25.4M | 27.3M | 17.2M | 40.7M | 41.2M |
| 總資產 | 101M | 110M | 120M | 137M | 178M | 165M | 264M | 293M | 366M | 424M | 460M | 515M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 109M | 119M | 115M | 120M | 359M | 340M | 466M | 484M | 552M | 586M | 576M | 575M |
| 股東權益 | −30.1M | −43.8M | −30.0M | −17.0M | −223M | −217M | −244M | −232M | −228M | −204M | −157M | −102M |
| 負債比 | 108.1% | 108.5% | 96.3% | 87.2% | 201.7% | 205.9% | 176.3% | 164.9% | 150.9% | 138.3% | 125.0% | 111.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −13.9M-611% | – | – | – | 2.7M | – | – | −59.3M | – | – | – |
| 資本支出 | – | 0.00 | – | – | – | 16K | – | – | 29K | – | – | – |
| 自由現金流 | – | −13.9M-614% | – | – | – | 2.7M | – | – | −59.3M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -371.5% | – | – | – | 98.7% | – | – | -233.9% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 6.4M
| Drug Product Revenue | 5.8M | 90.8% | -78.9% |
|---|---|---|---|
| Development And Other Revenue | 592K | 9.2% | -69.6% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 6.4M | -78.3% | 183M | 2,848.6% | 45.37 | −4.8M |
| FY2024 | 29.6M | -36.7% | −47.6M | -160.6% | -11.89 | −138M |
| FY2023 | 46.8M | -66.7% | −284M | -607.3% | -2.92 | −318M |
| FY2022 | 141M | -40.2% | −294M | -208.7% | -3.14 | −150M |
| FY2021 | 235M | +33.5% | −290M | -123.3% | -3.14 | −87.4M |
| FY2020 | 176M | -31.3% | −189M | -107.4% | -2.11 | 77.6M |
| FY2019 | 257M | +20.5% | −77.0M | -30.0% | -0.89 | −84.5M |
| FY2018 | 213M | – | −86.4M | -40.6% | -1.03 | −84.2M |